Establishing a zebrafish disease model drug screening platform (DANIO4CAN)


Project Coordinator: Dr. Martin Distel (PhD), Children´s Cancer Research Institute/Innovative Cancer Models

Project Partners:
Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, AUT
Ludwig Boltzmann Institute for Cancer Research, AUT
Ce-M-M - Research Center for Molecular Medicine of the Austrian Academy of Sciences, AUT
Research Center for Molecular Medicine, AUT
University of Veterinary Medicine Vienna, AUT
Medical University of Vienna, Institute for Cancer Research, AUT

Project Abstract:
Zebrafish has been proven to be a cost-effective model organism to identify therapeutic strategies for human diseases. The Children’s Cancer Research Institute (CCRI) aims at upgrading its established zebrafish cancer and rare childhood disease model drug screening pipeline. Currently, small compounds are tested on zebrafish disease models in a time-consuming manual way with image acquisition being done on a confocal microscope. This bottleneck is preventing unbiased medium/high throughput screening of potential therapeutics. Acquisition of a zebrafish sorter able to automatically administer zebrafish larvae into 96 well plates and an automated system for high resolution image acquisition will lead to the establishment of a unique, powerful zebrafish drug screening platform in Austria accelerating European preclinical translational research and offering new opportunities in the development of precision medicine.

Funded under the programme R&D Infrastructure Funding, 1st call, by the Austrian Research Promotion Agency (FFG)
Duration: 01.05.2017 – 30.04.2019
Link: https://www.ffg.at/FuE-Infrastrukturfoerderung_1_AS_gefoerderte_projekte